Literature DB >> 1440486

Early activation of hemostasis during cardiopulmonary bypass: evidence for thrombin mediated hyperfibrinolysis.

H Teufelsbauer1, S Proidl, M Havel, T Vukovich.   

Abstract

In 14 consecutive patients undergoing cardiopulmonary bypass for coronary bypass surgery the time course of coagulation and fibrinolysis markers were measured, e. g. plasma levels of thrombin-antithrombin III (TAT) complexes, cross-linked fibrin degradation products (XIFDP) and plasmin-alpha 2-antiplasmin complexes (PAP). TAT levels exceeded the 90% baseline percentile already during CPB (after opening of aortic clamp) in 10 patients, whereas PAP and XIFDP exceeded their 90% percentile in only one patient at this time. Concerning fibrinolysis markers PAP and XIFDP the majority of patients showed elevations higher than their 90% baseline percentile only 1 h postoperation. Correlation analysis revealed significant dependencies between TAT levels during and at the end of CPB and PAP levels 1 h postoperation (R = 0.55 and R = 0.56 respectively). Furthermore, 1 h postoperation XIFDP levels were significantly correlated with both TAT and PAP. Peak XIFDP levels at the same time correlated with blood loss via thoracic drains (R = 0.56). Thus, we suggest that hyperfibrinolysis in patients undergoing CPB is at least partly due to hypercoagulation. Clinically, this may implicate that intensified anticoagulation could prevent hyperfibrinolysis and reduce postoperative blood loss.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1440486

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  7 in total

Review 1.  The hemostatic defect of cardiopulmonary bypass.

Authors:  Matthew Dean Linden
Journal:  J Thromb Thrombolysis       Date:  2003-12       Impact factor: 2.300

2.  Autotransfusion management during and after cardiopulmonary bypass alters fibrin degradation and transfusion requirements.

Authors:  Alice Wiefferink; Patrick W Weerwind; Waander van Heerde; Steven Teerenstra; Luc Noyez; Ben E de Pauw; René M H J Brouwer
Journal:  J Extra Corpor Technol       Date:  2007-06

3.  Hyperfibrinolysis.

Authors:  B J Hunt; H Segal
Journal:  J Clin Pathol       Date:  1996-12       Impact factor: 3.411

4.  Tissue distribution and regulation of plasminogen activator inhibitor-1 in obese mice.

Authors:  F Samad; D J Loskutoff
Journal:  Mol Med       Date:  1996-09       Impact factor: 6.354

5.  Plasmin generation and fibrinolysis in pediatric patients undergoing cardiopulmonary bypass surgery.

Authors:  Vera Ignjatovic; Aparajith Chandramouli; Jenny Than; Robyn Summerhayes; Fiona Newall; Steve Horton; Andrew Cochrane; Paul Monagle
Journal:  Pediatr Cardiol       Date:  2011-10-02       Impact factor: 1.655

Review 6.  Coagulation disorders of cardiopulmonary bypass: a review.

Authors:  Domenico Paparella; Stephanie J Brister; Michael R Buchanan
Journal:  Intensive Care Med       Date:  2004-07-24       Impact factor: 17.440

Review 7.  Coagulation abnormalities in critically ill patients.

Authors:  Marcel Levi; Steven M Opal
Journal:  Crit Care       Date:  2006       Impact factor: 9.097

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.